At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test.
| Inventor | Institute |
|---|---|
| Mike Price | University of Nottingham |
| SKU: | 153397 |
|---|---|
| Product description: | MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence. Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. Medullary cystic kidney disease 1. |
| Alternate name: | CD227; KL6; Mucin 1; PEMT |
| Conjugation: | Unconjugated |
| Molecular weight: | 122 kDa |
| Immunogen: | need access to this paper to answer this – https://www.ncbi.nlm.nih.gov/pubmed/?term=fine+specificity+of+antibody+recognition+of+carcinoma-associated+epithelial+musincs |
| Cat. #: | 153397 |
|---|---|
| Provenance and Ownership: | The Anti-MUC1 [C789] is owned by Cancer Research UK. CancerTools supplies the Anti-MUC1 [C789] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-MUC1 [C789] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Ovarian cancer; Colorectal cancer; Breast cancer |
| Research Fields: | Cancer; Cell biology; Genetics |
| Application: | IHC |
| Target: | MUC1 |
| Reactivity: | Human ; Xenopus laevis |
| Clone: | C789 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence. Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. Medullary cystic kidney disease 1. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -80° C |
| Shipping conditions: | Dry ice |
| References: |
Croce et al. 1997. Anticancer Res. 17(6D):4287-92. PMID: 9494522. Expression of tumour associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.